Ha habido 50 transacciones internas recientes registradas para Dyne Therapeutics, Inc. (DYN), incluyendo 20 compras y 26 ventas. El total de compras internas fue valorado en $18.34M y el total de ventas internas en $11.85M.
Internos destacados con actividad reciente incluyen Lucera Erick, Posner Brian S, Kersten Dirk. Las transacciones internas pueden proporcionar información sobre cómo la dirección de la empresa ve la valoración y perspectivas futuras de la acción.
Operaciones de Insiders — DYN
| Fecha |
Nombre |
Cargo |
Tipo de Transacción |
Acciones |
Precio Promedio |
Valor |
Acciones en Propiedad |
| 2026-04-01 |
Lucera Erick |
Chief Financial Officer |
Venta Informativa |
5,727 |
$18.64 |
$106.75K |
125,373 |
| 2026-03-30 |
Posner Brian S |
Director |
Compra Informativa |
2,000 |
$17.08 |
$34.16K |
15,500 |
| 2026-03-11 |
Posner Brian S |
Director |
Compra Informativa |
2,000 |
$19.35 |
$38.7K |
13,500 |
| 2026-03-11 |
Kersten Dirk |
Director |
Venta Informativa |
129,672 |
$19.52 |
$2.53M |
4,644,386 |
| 2026-03-10 |
Kersten Dirk |
Director |
Venta Informativa |
281,858 |
$19.80 |
$5.58M |
4,774,058 |
| 2026-03-09 |
Kersten Dirk |
Director |
Venta Informativa |
177,690 |
$17.72 |
$3.15M |
5,285,156 |
| 2026-03-06 |
Posner Brian S |
Director |
Compra Informativa |
3,000 |
$15.06 |
$45.18K |
11,500 |
| 2026-03-05 |
Cox John |
CEO & President |
Venta Informativa |
2,732 |
$14.90 |
$40.71K |
374,145 |
| 2026-03-05 |
Kerr Douglas |
Chief Medical Officer |
Venta Informativa |
904 |
$14.90 |
$13.47K |
171,606 |
| 2026-03-05 |
Friedl-naderer Johanna |
Chief Commercial Officer |
Venta Informativa |
148 |
$14.90 |
$2.21K |
154,581 |
| 2026-02-12 |
Cox John |
CEO & President |
Concesión de RSU |
285,000 |
$16.00 |
$4.56M |
285,000 |
| 2026-02-12 |
Lucera Erick |
Chief Financial Officer |
Concesión de RSU |
105,000 |
$16.00 |
$1.68M |
105,000 |
| 2026-02-12 |
Kerr Douglas |
Chief Medical Officer |
Concesión de RSU |
130,000 |
$16.00 |
$2.08M |
130,000 |
| 2026-02-12 |
Friedl-naderer Johanna |
Chief Commercial Officer |
Concesión de RSU |
90,000 |
$16.00 |
$1.44M |
90,000 |
| 2025-12-22 |
Karnani Vikram |
Officer |
Desconocido |
- |
- |
- |
- |
| 2025-12-22 |
Karnani Vikram |
Director |
Concesión de RSU |
59,665 |
$20.78 |
$1.24M |
59,665 |
| 2025-12-05 |
Cox John |
CEO & President |
Venta Informativa |
2,662 |
$20.72 |
$55.16K |
196,877 |
| 2025-12-05 |
Kerr Douglas |
Chief Medical Officer |
Venta Informativa |
880 |
$20.72 |
$18.23K |
87,510 |
| 2025-12-05 |
Friedl-naderer Johanna |
Chief Commercial Officer |
Venta Informativa |
144 |
$20.72 |
$2.98K |
94,729 |
| 2025-10-01 |
Posner Brian S |
Director |
Desconocido |
- |
- |
- |
8,500 |
| 2025-10-01 |
Posner Brian S |
Director |
Concesión de RSU |
70,000 |
$12.50 |
$875K |
70,000 |
| 2025-09-05 |
Kerr Douglas |
Chief Medical Officer |
Venta Informativa |
873 |
$13.41 |
$11.71K |
88,390 |
| 2025-09-05 |
Friedl-naderer Johanna |
Chief Commercial Officer |
Venta Informativa |
144 |
$13.41 |
$1.93K |
94,873 |
| 2025-09-05 |
Cox John |
CEO & President |
Venta Informativa |
2,640 |
$13.41 |
$35.4K |
199,539 |
| 2025-09-04 |
Kerr Douglas |
Chief Medical Officer |
Venta Informativa |
3,552 |
$13.27 |
$47.14K |
89,263 |
| 2025-09-04 |
Friedl-naderer Johanna |
Chief Commercial Officer |
Venta Informativa |
894 |
$13.27 |
$11.86K |
95,017 |
| 2025-07-16 |
Cox John |
CEO & President |
Concesión de RSU |
197,285 |
$9.33 |
$1.84M |
197,285 |
| 2025-07-16 |
Kerr Douglas |
Chief Medical Officer |
Concesión de RSU |
65,110 |
$9.33 |
$607.48K |
65,110 |
| 2025-07-16 |
Friedl-naderer Johanna |
Chief Commercial Officer |
Concesión de RSU |
51,255 |
$9.33 |
$478.21K |
51,255 |
| 2025-07-15 |
Cox John |
CEO & President |
Donación (Otorgada) |
10,000 |
- |
- |
202,179 |
| 2025-07-14 |
Cox John |
CEO & President |
Compra Informativa |
100,000 |
$9.11 |
$911K |
242,179 |
| 2025-06-05 |
Cox John |
CEO & President |
Venta Informativa |
4,060 |
$13.35 |
$54.2K |
142,179 |
| 2025-06-05 |
Kerr Douglas |
Chief Medical Officer |
Venta Informativa |
1,342 |
$13.35 |
$17.92K |
92,815 |
| 2025-06-05 |
Friedl-naderer Johanna |
Chief Commercial Officer |
Venta Informativa |
146 |
$13.35 |
$1.95K |
95,911 |
| 2025-05-30 |
Hurwitz Edward |
Director |
Concesión de RSU |
35,000 |
$11.96 |
$418.6K |
35,000 |
| 2025-05-30 |
Lubner David Charles |
Director |
Concesión de RSU |
35,000 |
$11.96 |
$418.6K |
35,000 |
| 2025-05-30 |
Rhodes Jason P |
Director |
Concesión de RSU |
35,000 |
$11.96 |
$418.6K |
35,000 |
| 2025-05-30 |
Stehman-breen Catherine |
Director |
Concesión de RSU |
35,000 |
$11.96 |
$418.6K |
35,000 |
| 2025-05-30 |
Kersten Dirk |
Director |
Concesión de RSU |
35,000 |
$11.96 |
$418.6K |
35,000 |
| 2025-05-30 |
Incerti Carlo |
Director |
Concesión de RSU |
35,000 |
$11.96 |
$418.6K |
35,000 |
| 2025-03-31 |
Lucera Erick |
Officer |
Desconocido |
- |
- |
- |
- |
| 2025-03-31 |
Lucera Erick |
Chief Financial Officer |
Concesión de RSU |
66,100 |
- |
- |
66,100 |
| 2025-03-13 |
Friedl-naderer Johanna |
Chief Commercial Officer |
Venta Informativa |
143 |
$12.12 |
$1.73K |
96,057 |
| 2025-03-11 |
Scalzo Richard William |
SVP, Head of Finance & Admin. |
Venta Informativa |
1,343 |
$11.38 |
$15.28K |
122,330 |
| 2025-03-11 |
Beskrovnaya Oxana |
Chief Scientific Officer |
Venta Informativa |
2,153 |
$11.38 |
$24.5K |
195,840 |
| 2025-03-05 |
Cox John |
CEO & President |
Venta Informativa |
4,061 |
$11.83 |
$48.04K |
146,239 |
| 2025-03-05 |
Scalzo Richard William |
SVP, Head of Finance & Admin. |
Venta Informativa |
917 |
$11.83 |
$10.85K |
123,673 |
| 2025-03-05 |
Kerr Douglas |
Chief Medical Officer |
Venta Informativa |
1,343 |
$11.83 |
$15.89K |
94,157 |
| 2025-03-05 |
Beskrovnaya Oxana |
Chief Scientific Officer |
Venta Informativa |
1,094 |
$11.83 |
$12.94K |
197,993 |
| 2025-02-18 |
Scalzo Richard William |
SVP, Head of Finance & Admin. |
Venta Informativa |
2,488 |
$13.95 |
$34.71K |
124,590 |
■ Informativa — transacción en mercado abierto (más significativa)
■ No informativa (compra) — premio, ejercicio de opción, conversión
■ No informativa (venta) — retención fiscal, venta de adjudicación
■ Neutral — regalo, fideicomiso, vencimiento
